Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma

References

• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini R M, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113–1120
   PubMed Web of Science ®Google Scholar
• Muris J J, Meijer C J, Vos W, van Krieken J H, Jiwa N M, Ossenkoppele G J, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723
   PubMed Web of Science ®Google Scholar
• De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060–7068
   PubMed Web of Science ®Google Scholar
• Bai M, Agnantis N J, Skyrlas A, Tsanou E, Kamina S, Galani V, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol 2003; 16: 471–480
   PubMed Web of Science ®Google Scholar
• Bai M, Skyrlas A, Agnantis N J, Kamina S, Kitsoulis P, Kanavaros P. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res 2004; 24: 3081–3088
   PubMed Web of Science ®Google Scholar
• Bai M, Skyrlas A, Agnantis N J, Kamina S, Tsanou E, Grepi C, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol 2004; 17: 847–856
   PubMed Web of Science ®Google Scholar
• Hill M E, MacLennan K A, Cunningham D C, Vaughan Hudson B, Burke M, Clarke P, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88: 1046–1051
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, d'Agay M F, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265–272
   PubMed Web of Science ®Google Scholar
• Gascoyne R D, Adomat S A, Krajewski S, Krajewska M, Horsman D E, Tolcher A W, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Barrans S L, Carter I, Owen R G, Davies F E, Patmore R D, Haynes A P, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma – a Nordic Lymphoma Group study. Ann Hematol 2004; 83: 414–419
   PubMed Web of Science ®Google Scholar
• Sanchez E, Chacon I, Plaza M M, Munoz E, Cruz M A, Martinez B, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16: 1931–1939
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli V T, Wright G, Dave B J, Horsman D E, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
   PubMed Web of Science ®Google Scholar
• Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13–20
   PubMed Web of Science ®Google Scholar
• Bullwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006; 206: 624–635
   PubMed Web of Science ®Google Scholar
• Gerdes J, Stein H, Pileri S, Rivano M T, Gobbi M, Ralfkiaer E, et al. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987; 2: 448–449
   PubMed Web of Science ®Google Scholar
• Grogan T M, Lippman S M, Spier C M, Slymen D J, Rybski J A, Rangel C S, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157–1160
   PubMed Web of Science ®Google Scholar
• Miller T P, Grogan T M, Dahlberg S, Spier C M, Braziel R M, Banks P M, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460–1466
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Chan W C, Aoun P, Cochran G T, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377–1384
   PubMed Web of Science ®Google Scholar
• Nakamine H, Bagin R G, Vose J M, Bast M A, Bierman P J, Armitage J O, et al. Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma. Cancer 1993; 71: 3130–3137
   PubMed Web of Science ®Google Scholar
• Kossakowska A E, Huchcroft S, Boras V, Urbanski S J. Prognostic significance of proliferative activity of diffuse large cell lymphomas. Hematol Pathol 1991; 5: 101–107
   PubMedGoogle Scholar
• Tzankov A, Gschwendtner A, Augustin F, Fiegl M, Obermann E C, Dirnhofer S, et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006; 12: 2125–2132
   PubMed Web of Science ®Google Scholar
• Obermann E C, Went P, Pehrs A C, Tzankov A, Wild P J, Pileri S, et al. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep 2005; 14: 1461–1467
   PubMed Web of Science ®Google Scholar
• Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8: 729–733
   PubMedGoogle Scholar
• Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson P O. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma – a population-based study. Leuk Lymphoma 2007; 48: 736–745
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Hoyer K K, Pang M, Gui D, Shintaku I P, Kuwabara I, Liu F T, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 2004; 164: 893–902
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith T L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343–346
   PubMedGoogle Scholar
• Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2: 365–371
   PubMedGoogle Scholar
• Slymen D J, Miller T P, Lippman S M, Spier C M, Kerrigan D P, Rybski J A, et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 986–993
   PubMed Web of Science ®Google Scholar
• Leoncini L, Del Vecchio M T, Megha T, Barbini P, Galieni P, Pileri S, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993; 142: 755–763
   PubMed Web of Science ®Google Scholar
• Wilson W H, Teruya-Feldstein J, Fest T, Harris C, Steinberg S M, Jaffe E S, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601–609
   PubMed Web of Science ®Google Scholar
• Vairo G, Innes K M, Adams J M. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13: 1511–1519
   PubMed Web of Science ®Google Scholar
• Greider C, Chattopadhyay A, Parkhurst C, Yang E. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 2002; 21: 7765–7775
   PubMed Web of Science ®Google Scholar
• Shaffer A L, Yu X, He Y, Boldrick J, Chan E P, Staudt L M. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199–212
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile J F, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Wilson K S, Sehn L H, Berry B, Chhanabhai M, Fitzgerald C A, Gill K K, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 1102–1109
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg M L, Taskinen M, Berglund M, Amini R M, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935
   PubMed Web of Science ®Google Scholar